VRCA Verrica Pharmaceuticals Inc.

NASDAQ
$4.97

Verrica Pharmaceuticals Inc. (VRCA) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.59 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.4% since its last earnings release on August 6, 2026.

Verrica Pharmaceuticals Reported Earnings
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:00 PM ET
Earnings Whisper
-
vs ($0.59)
Rev est $6.49M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.06

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions.

Sector

Healthcare

Industry

Drug Manufacturers/Other